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Abstract
Introduction: This study aimed to characterize the glycophenotype of osteoarthritic cartilage and human
chondrocytes.
Methods: Articular knee cartilage was obtained from nine osteoarthritis (OA) patients. mRNA levels for 27
glycosyltransferases were analyzed in OA chondrocytes using RT-qPCR. Additionally, N- and O-glycans were
quantified using mass-spectrometry. Histologically, two cartilage areas with Mankin scores (MS) either ≤4 or ≥9
were selected from each patient representing areas of mild and severe OA, respectively. Tissue sections were
stained with (1) a selected panel of plant lectins for probing into the OA glycophenotype, (2) the human lectins
galectins-1 and -3, and (3) the glycoprotein asialofetuin (ASF) for visualizing β-galactoside-specific endogenous
lectins.
Results: We found that OA chondrocytes expressed oligomannosidic structures as well as non-, mono- and
disialylated complex-type N-glycans, and core 2 O-glycans. Reflecting B4GALNT3 mRNA presence in OA
chondrocytes, LacdiNAc-terminated structures were detected. Staining profiles for plant and human lectins were
dependent on the grade of cartilage degeneration, and ASF-positive cells were observed in significantly higher
rates in areas of severe degeneration.
Conclusions: In summary, distinct aspects of the glycome in OA cartilage are altered with progressing
degeneration. In particular, the alterations measured by galectin-3 and the pan-galectin sensor ASF encourage
detailed studies of galectin functionality in OA.
Introduction
The emerging concept of the ‘sugar code’ has fundamen-
tally changed our understanding of the significance of gly-
cosylation [1]. Structures that were initially seen as an
appendix solely modulating physicochemical properties of
proteins turned out to be bioactive with high-density cod-
ing capacity. In fact, glycans of cellular glycoconjugates are
intimately involved in diverse processes of cell-cell and
cell-matrix interactions [1]. Work on hereditary diseases
and murine models with engineered genetic deficiencies
in glycosylation has revealed ample connections to ap-
parent dysfunctions [2,3]. Insights into T cell activation
and tumor suppressor-dependent changes of glycogene
(glycosyltransferases, lectins) expression, for instance, have
exemplified how swift reprogramming of distinct aspects
of the glycophenotype elicits growth regulation [4-11].
Among others, these cases demonstrate that substitutions
of the N-glycan core, known to act as switches for cis/
trans-interactions [1,12], and the status/linkage type of
sialylation are particularly prone to marked regulation: a
result that guides the selection of tools (for example,
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lectins [13]) to monitor these aspects of the glyco-
phenotype under disease conditions.
Osteoarthritis (OA), clinically characterized by pain,
stiffness, joint effusion and loss of joint function/mobility,
is a degenerative joint disease whose onset can depend on
genetic, constitutional and biomechanical risk factors.
Major cellular hallmarks of OA pathobiology include
hypertrophic differentiation or apoptosis of chondrocytes,
impaired cell adhesion and pro-inflammatory signaling
that promotes the breakdown of the cartilage extracellular
matrix [14]. Little is known, however, about the role of the
cellular glycophenotype in the onset and progression of
OA. In previous reports, we have focused on the cha-
racterization of glycan expression of immortalized human
chondrocytes and cells from primary cultures [15,16].
Complemented with transcriptional profiling of selected
glycosyltransferases and identification of the most
abundant N/O-glycans, we described the impact of pro-
inflammatory cytokines interleukin-1β and tumor necrosis
factor-α on the glycan profile of chondrocytes [17,18]. The
in vitro nature of these studies, however, did not allow
addressing the role of modulated glycosylation in joint
disease. The present work was therefore designed to test
the hypothesis that the glycosylation signature of chondro-
cytes and extracellular matrix is affected in OA cartilage
in vivo during disease progression. Accordingly, we here
report on the lectin histochemical analysis of sections
from articular cartilage of OA patients. In addition to the
plant lectins listed in Table 1, we tested human lectins as
probes, with the intention of defining chondrocyte reactiv-
ity for galectins, known to be endogenous adhesion/
growth-regulatory effectors on the cell surface and intra-
cellularly [19]. When labeled, these probes enable the
delineation of the status and any alterations of cellular
Table 1 Panel of lectins (plant agglutinins and human galectins) used for glycophenotyping of human OA cartilage
Plant and lectins Abbreviation Monosaccharide
specificity
Optimized
concentration
(ng/μl)
Potent oligosaccharide/glycoprotein glycan ligands
Canavalia ensiformis
(jack bean) agglutinin
ConA Man/Glc 0.5 Manα6(Manα3)Manβ4GlcNAcβ4GlcNAc
Pisum sativum (pea)
agglutinin
PSA Man/Glc 0.5 N-glycan binding enhanced by core fucosylation
Phaseolus vulgaris
(kidney bean)
erythroagglutinin
PHA-E a 1 Bisected complex-type N-glycans: Galβ3/4GlcNAcβ2Manα6
(GlcNAcβ2-Manα3)(GlcNAcβ4)Manβ4GlcNAcβ4GlcNAc
Phaseolus vulgaris
(kidney bean)
leukoagglutinin
PHA-L a 1 Tetra- and triantennary N-glycans with β6-branching
Viscum album
(mistletoe) agglutinin
VAA Gal 0.5 Galβ3(4)GlcNAc without/with α2,6-sialylation, Galα3(4)Gal, Galβ2(3)Gal,
Fucα2Gal
Lycopersicon esculentum
(tomato) agglutinin
LEA a 2 core and stem regions of high-mannose-type N-glycans,
(GlcNAcβ3Galβ4GlcNAcβ3Gal) repeats (LacDiNAc to polyLacNAc)
Maackia amurensis
agglutinin-I
(leukoagglutinin)
MAA-I a 20 Neu5Ac/Gcα3Galβ4GlcNAc/Glcb, 3′-sulfation instead of sialylation and
9′-O-acetylation tolerated
Sambucus nigra
(elderberry) agglutinin
SNA Gal/GalNAc 0.4 Neu5Ac/Gcα6Gal/GalNAcc, clustered Tn-antigen, 9′-O-acetylation
tolerated
Dolichos biflorus (horse
gram) agglutinin
DBA GalNAc 50 GalNAcα3GalNAcα3Galβ4Galβ4Glc, clustered Tn-antigen, histo-blood
group A- tetrasaccharide, β-linked GalNAc in Sda antigen
Arachis hypogaea
(peanut) agglutinin
PNA Gal 0.7 Galβ3GalNAcα/β
Artocarpus integrifolia
(jack fruit) agglutinin
Jacalin (JAC) Gal/GalNAc 0.7 Galβ3GalNAcα, sialylation of T/Tn antigens tolerated
Galectin-1 Gal-1 d 1 Type I/II disaccharides (α2,3-sialylation/sulfation tolerated), LacNAc
repeats (terminal α2,6-sialylation not tolerated), Fucα2Gal, extended
core 2/4 structures, multiantennary N-glycans
Galectin-3 Gal-3 d 1 Type I/II and core 1 disaccharides (α2,3-sialylation/sulfation tolerated),
LacNAc repeats (terminal α2,6-sialylation tolerated), GalNAcβ4GlcNAc
(LacdiNAc), Galα3Galβ4GlcNAc, histo-blood group ABH epitopes,
multiantennary N-glycans/clustered T-antigen
ano monosaccharide known as ligand; bbinding specific for type II LacNAc (Galβ4GlcNAc) core [32]; cbinding of type I LacNAc (Galβ3GlcNAc) core preferred,
6′-sulfation of GlcNAc in α2,6-sialylated LacNAc (type I/II) enhances affinity [33]; dextension of Gal core to disaccharide (mostly in β-linkage such as Galβ2Gal or
Galβ4Glc) required.
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binding capacity, with the potential to detect disease-
associated changes [5,20,21]. Homodimeric proto-type
galectin-1 (Gal-1) and chimera-type galectin-3 (Gal-3)
were selected, because Gal-1 is implicated in the regula-
tion of chondrocyte growth/catabolism, while Gal-3 ap-
pears to exert a protective role on articular cells [22-24].
Of note, Gal-1 is an abundant cellular protein in human
mesenchymal stem cells, supposedly relevant for cell-
matrix interactions already at this early stage of develop-
ment [25]. Its avian orthologue CG-1A participates, at a
very early stage, in the formation and patterning of
precartilage mesenchymal condensations in the develop-
ing limb, indicating fundamental functionality across
phylogenetic boundaries [26]. Gal-3 has received attention
in histopathology due to its diagnostic potential for thy-
roid lesions and, of note, can competitively interfere with
Gal-1 activities [27-29]. Finally, we introduce asialofetuin
(ASF), a glycoprotein that presents β-galactosides for
lectin binding [30], to localize respective tissue lectins in
cartilage in situ. The application of carrier-immobilized
carbohydrate ligands in lung tumor sections had disclosed
a correlation of binding to prognosis, intimating biological
relevance beyond mapping [31]. Using plant and endogen-
ous lectins as well as the labeled glycoproteins, our results
define the glycophenotype in OA cartilage focusing on
function-oriented aspects, and illustrate the feasibility of
visualizing carbohydrate-binding capacity in this system
glycohistochemically.
Methods
Clinical specimens
Human articular cartilage was obtained during total
knee replacement surgeries in patients with OA (n = 9)
with informed consent and in accordance with the terms
of the ethics committee of the Medical University of
Vienna (EK-No.: 1065/2011). Details on clinical speci-
mens are given in Additional file 1: Table S1.
Cell culture
Primary human OA chondrocytes were enzymatically
isolated from femoral condyles and tibial plateaus of ar-
ticular OA cartilage (n = 5) following established pro-
tocols [16-18]. Isolated chondrocytes were cultured in
(Dulbecco’s) modified Eagle’s medium ((D)MEM; Gibco,
Lofer, Austria) containing 10% fetal calf serum (FCS;
Biochrom, Berlin, Germany) and 2 μl/ml gentamycin
(Biochrom) in a humidified atmosphere of 5% CO2/95%
air at 37°C. For all assays, only freshly isolated and seeded
cells without subculturing were used.
Quantitative real-time RT-PCR
Chondrocytes were grown in 12-well tissue culture
plates (Iwaki, Tokyo, Japan) to 90% confluence. Total
RNA was extracted using the NucleoSpin RNA II Kit
(Macherey-Nagel, Düren, Germany). Each sample was run
on the Agilent 2100 Bioanalyzer Nano LabChip for quality
control and quantification of total RNA prior to reverse
transcription into cDNA using the high capacity cDNA
reverse transcription kit (Applied Biosystems, Vienna,
Austria). RNA integrity numbers were between 9.6 and 10.
SYBR-green based qPCR assays for the glycosyltransfer-
ase transcripts were used as described previously [17,18].
The primers for B4GALNT3 (NM_173593; Forward:
TGTTGAGATGGCACTGAAGAG; Reverse: TGGAGGT
CACAGAGGAAGATG), an enzyme responsible for pro-
ducing GalNAcβ4GlcNAc (LacdiNAc) termini [34], were
designed using AlleleID software. In melting curve ana-
lysis, only one peak was observed confirming target speci-
ficity. Amplification efficiencies of primers were assessed
using dilution series of cDNA prepared from chondrocyte
mRNA. mRNA expression levels were calculated as
relative copy numbers considering actual amplification
efficiencies and with respect to that of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) set at 1,000. Tech-
nically, the protocol deliberately followed the minimal
guidelines for the design and documentation of qPCR
experiments as recently outlined [35]. A qPCR checklist
listing all relevant information is provided to assess
the technical adequacy of the used qPCR protocols (see
Additional file 2: Table S2).
Protein and glycan preparation, quantification of
oligosaccharides using LC-ESI-MS
The quantification of oligosaccharides using liquid
chromatography-electrospray ionization-mass spectrom-
etry (LC-ESI-MS) essentially followed previously described
protocols [17,18]. Briefly, cultured OA chondrocytes were
lysed and precipitated proteins were subjected to SDS-
PAGE. Free N-glycans were obtained after trypsin and
PNGase F digestions. O-Glycans were released by redu-
cing β-elimination and further analyzed as done for
borohydride-reduced N-glycans. Analysis of the glycans
(from an aliquot equivalent to 2.5 × 105 cells) by positive-
ion LC-ESI-MS was performed with a 100 × 0.32 mm por-
ous graphite carbon (PGC) column (Thermo, Vienna,
Austria) at a flow rate of 5 μl/min maintained with a
Dionex Ultimate 3000 cap flow system. Mass spectrometry
was done using a Waters Q-TOF Ultima Global mass
spectrometer with standard ESI source and MassLynx V4.0
SP4 software. The peak heights of the deconvoluted spec-
tra as generated with the MaxEnt3 routine of MassLynx
V4.0 served as measures for relative molar abundance.
Histological assessment
For immunohistochemistry, tissue specimens from femoral
condyles were selected macroscopically to provide one area
of mild and one area of severe degeneration whenever pos-
sible. The specimens were fixed in formalin and decalcified
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using Titriplex-Tris-Solution (Gatt-Koller, Absam, Austria)
prior to embedding in paraffin according to standard pro-
cedures. Paraffin sections (2.5 μm) were stained with
safranin-O (Sigma, Vienna, Austria) and counter-stained
using light-green Goldner III solution (Morphisto, Frankfurt,
Germany). Using the Mankin scale, the degree of cartilage
degeneration in the sections was graded according to histo-
logical and histochemical characteristics [36]. The Mankin
score (MS) considers abnormalities in cartilage structure,
cell population, safranin O stain distribution and tidemark
integrity, and results in a final grade ranging from 0 (most
intact) to 14 (most degenerated). From each patient, two
areas with MS ≤4 and MS ≥9 were selected, representing
one area of mild and one area of severe degeneration,
respectively. Consecutive sections were then processed for
lectin histochemical staining as described below.
Lectin histochemistry
All lectin probes used for glycan mapping and their respect-
ive carbohydrate specificities are listed in Table 1. The plant
lectins DBA, JAC, LEA, MAA-I, PHA-E, PHA-L, PNA and
SNA were obtained as biotinylated probes from Vector
Labs Burlingame, CA, USA. The Viscum album agglutinin
(VAA; from extracts of leaves [37]) and the galectins (from
recombinant production) were purified by affinity chro-
matography on lactosylated Sepharose 4B, obtained after
divinyl sulfone activation, ConA and PSA (from seeds)
on mannosylated Sepharose 4B, biotinylated under
activity-preserving conditions and rigorously checked for
maintained activity by solid-phase/cell assays as described
[5,20,38]. Bovine fetuin was chemically desialylated by
acid/heat treatment to yield ASF, which was biotinylated
as described [39], followed by ascertaining galectin reactiv-
ity in solid-phase assays using labeled Gal-1/-3 as sensors.
Performing titration experiments, optimal lectin con-
centrations that yielded best signal-to-background ra-
tios were determined and kept constant for processing
within this comparative study (all listed in Table 1). Fol-
lowing deparaffinization, the tissue sections were washed
twice with PBS for 5 minutes, then exposed to PBS/H2O2
(200 ml PBS mixed with 6 ml 30% H2O2) to block en-
dogenous peroxidase activity for three minutes and finally
washed again twice with PBS. The biotinylated lectins were
diluted with 2% BSA/HEPES and the biotinylated galectins
were diluted with 2% BSA/PBS. Epitope-independent bind-
ing was blocked by preincubation with the respective BSA
solutions for 30 minutes at room temperature. The sec-
tions were then incubated overnight with the biotinylated
probes at 4°C and, after thorough washing, developed
using the VECTASTAIN Elite ABC Kit (Vector Labs)
with NovaRED peroxidase substrate kit (Vector Labs).
Counterstaining was performed using Mayer’s hemalum
solution (Merck, Vienna, Austria). Thereafter, sections
were thoroughly rinsed and mounted for microscopy. The
omission of biotinylated probes from the process or com-
petitive inhibition (by lactose) was performed to test the
carbohydrate dependence of lectin histochemistry. The
samples were evaluated using an Olympus Vanox AHBT3
microscope and the images were processed using cell^D
software (Olympus). Staining intensities above background
levels were scored as positive. The staining of chondrons
and interterritoreal matrix of mildly degenerated (MS ≤4;
n = 7) and severely degenerated (MS ≥9; n = 9) areas was
assessed independently by two observers. Cooperative ana-
lysis of discordant slides led to consensus in all cases.
The percentage of ASF-reactive chondrocytes in the
areas of mild and severe degeneration was determined
by evaluating the fraction of stained cells at a magnifica-
tion of 20× on the basis of 100 chondrocytes per area
(starting from the cartilage surface). For statistical
analysis of the data, a paired t-test following control
for Gaussian distribution was performed using the
Microsoft Excel integrated analysis tool. In accordance
with recent guidelines [40], all analysis units (n) given in
figure and table legends refer to the number of inde-
pendent observations (biological replicates) underlying
the respective descriptive statistics and statistical tests.
Glycocytochemistry
OA chondrocytes were seeded on glass coverslips placed
into 24-well plates. Cells were fixed with 400 μl ice-cold
methanol for 20 minutes and rehydrated in 700 μl PBS
for 20 minutes at room temperature. Cells were incu-
bated with 250 μl of solution containing biotinylated
ASF (20 μg/ml in 1% BSA/PBS) for 1 hour at 37°C. After
three washing steps with PBS, cells were incubated for 1
hour at 37°C with streptavidin-PE (diluted 1:40 in 1%
BSA/PBS; Sigma) and 300 nM DAPI (Invitrogen,
Darmstadt, Germany). After washing three times with
PBS, cells were embedded in FluorSaveTM Reagent
(Calbiochem, San Diego, CA, USA) for microscopic
inspection at 62× magnification using a Carl Zeiss LSM
700 Laser Scanning Microscope and Zen software.
Results
Expression of selected glycosyltransferase genes
As a first parameter of the glycophenotype of OA
chondrocytes, mRNA levels of glycosyltransferases were
quantified using RT-qPCR (for details on enzyme func-
tions, please see the legend of Table 2; for further infor-
mation, please see Carbohydrate-Active Enzyme (CAZy)
database [41]). As listed in Table 2, we included key en-
zymes involved in processing, branching and sialylation
of N-glycans and O-glycans, along with three chondro-
cyte markers as internal controls as previously reported
[16]. The rich levels of COL2 and ACG as well as the
differentiation index COL2/COL1 ascertained the chon-
drocyte phenotype of cultured cells in this study.
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The enzyme profile let us expect synthesis of complex-
type N-glycan (MAN2A1, MGAT2) with core substitu-
tions (FUT8, MGAT3) and branching (MGAT4, MGAT5).
The considerable level of B4GALNT3 expression by OA
chondrocytes suggested the presence of LacdiNAc termini
in N-glycans of OA chondrocytes. Of note for O-glycans,
expression of GALNT1 (from the complexity of this en-
zyme family, we focused on this representative major
member [42,43]), B3GNT2 and GCNT enables produc-
tion of core 2 glycans with LacNAc repeats. Sialylation
can also be expected (Table 2).
In principle, these data reveal fulfillment of an essen-
tial prerequisite for glycan biosynthesis but should not
be interpreted to reliably predict quantitative aspects
of actual glycosylation. Correct positioning of the gene
products within the glycosylation machinery and avail-
ability of substrates, among others, are factors playing
into the production of glycans. Thus, to provide insights
into the glycome, we monitored the presence of glycans
by LC-ESI-MS.
Profiling of N-and O-glycans
Structures of the glycoprotein-derived N- and O-glycans
from OA chondrocytes are listed in Figure 1, together with
quantitative data, with emphasis on glycans not present in
the culture medium to avoid contamination. Meeting the
expectations from RT-qPCR profiling, the glycan popula-
tion detected includes core-substituted, α2,3/6-sialylated
N-glycans, with the presence of LacdiNAc-terminated
structures and core 2 O-glycans. This mapping provides a
quantitative view of glycan structures presented by OA
chondrocytes. Together with the data in Table 2, these
results allowed us to strategically set up the panel of plant
lectins for probing into the OA glycophenotype, in terms
of presence/absence of distinct determinants and spatial as-
pects (for a survey of lectin specificities, please see Table 1).
Glycophenotyping by plant lectins
Each lectin was systematically tested by titration to de-
termine the optimal concentration for reaching the best
signal-to-background ratio. At this concentration,
which is listed in Table 1, inhibition by cognate sugar
ascertained the reactivity, as illustrated in Figure 2a for
blocking typical binding to chondrocytes and extracellular
matrix. In addition, omission of the incubation step with
labeled lectin from routine processing enabled us to
exclude lectin-independent signal generation (Figure 2b).
Additional file 3: Table S3 presents a quantitative overview
of lectin-binding patterns, as a function of the MS. In
detail, flanked by respective representative illustrations,
lectin binding was characterized as follows:
Con A, in contrast to the other lectins, stained all mildly
and severely degenerated cartilage regions. Chondrons in
both mildly (100%; 7/7) and severely degenerated (100%;
9/9) specimens were positive (see Additional file 3: Table
S3). Cells were stained in the middle and deeper zones in
mildly degenerated areas (Figure 2c), whereas severely
degenerated areas showed cell staining throughout the en-
tire cartilage (Figure 2d), strong reactivity of blood vessels
and osteocytes was observed, and the subchondral bone
matrix remained unstained (not shown).
PSA, reactive with core-fucosylated N-glycans, stained
OA cartilage with a quantitative difference according to
the MS (see Additional file 3: Table S3). In the majority
of severely degenerated areas, the interterritorial matrix
presented intense reactivity (Figure 2e). Comparable to
ConA, the subchondral bone matrix was negative,
whereas osteocytes and blood vessels bound the lectin
(not shown).
PHA-E stained chondrocytes in mildly degenerated
regions (2/7; 29%) less frequently and intensely than in
severely degenerated regions (5/9; 56 %; Figure 2f, g;
Additional file 3: Table S3). The interterritorial matrix was
negative in less degenerated cartilage (0/7; 0%). but reac-
tive in more degenerated areas (4/9; 44%). Pannus-like
Table 2 Presence of mRNA for selected glycosyltransferases
in OA chondrocytes
N-glycans
MAN1C1 0.8 MGAT4A 172.6 ST6Gal1 676.8
MAN2A1 449.9 MGAT4B 77.0 ST6Gal2 5.2
MGAT1 723.3 MGAT5A 387.3 ST3Gal3 59.4
MGAT2 2,328.2 MGAT5B 2.9 ST3Gal4 153.7
MGAT3 10.1 FUT8 263.9 ST3Gal6 14.7
B4GALNT3 104.4
O-glycans Chondrocyte markers
GALNT 3,925.3 ST3Gal1 60.4 AGC 1,704.7
B3GNT 141.8 ST3Gal2 75.7 COL2 9,953.7
GCNT1 375.5 ST6GalNAc1 n.d. COL1 5,722.9
FUT1 0.4 ST6GalNAc2 n.d.
3OST 19.4 ST6GalNAc3 0.7
ST6GalNAc4 9.8
Distinct mRNA species were quantified using RT-qPCR. Numbers denote
relative copy numbers with respect to the expression of the GAPDH gene
arbitrarily set at 1,000. cDNA of OA chondrocytes from five donors was pooled
and analyzed in duplicate. All series of measurements (technical replicates)
had a standard deviation below 1.5%.
MAN2A1 and MGAT2: conversion of oligomannosides to complex-type
N-glycans. MGAT1: committing step for synthesis of hybrid- and complex-type
N-glycans. MAN1C1: trimming of oligomannosidic structures. MGAT3:
introduction of bisecting GlcNAc to the core of complex-type glycans in β1,
4-linkage. MGAT4 and MGAT5: production of tri- and tetra-antennary N-linked
sugar chains. FUT8: transfer of fucose to the core of complex-type glycans in
α1,6-linkage. B4GALNT3: β1,4-N-acetylgalactosaminyltransferase 3, forming the
LacdiNAc terminus. ST6GAL1, ST6GAL2: N-glycan α2,6-sialyltransferases.
ST3GAL3, ST3GAL4, ST3GAL6: N-glycan α2,3-sialyltransferases. GALNT1: initiates
O-linked mucin-type glycosylation in the Golgi apparatus. B3GNT2: a major
poly-N-acetyllactosamine synthase. GCNT: formation of the core 2 O-glycan
branch. FUT1: O-glycan fucosyltransferase. 3OST: sulfotransferase for the
3′-position of galactose. ST3GAL1 and ST3GAL2: O-glycan α2,3-
sialyltransferases. ST6GALNAC1, ST6GALNAC2, ST6GALNAC3 and ST6GALNAC4:
O-glycan α2,6-sialyltransferases acting on GalNAc as acceptor. AGC: aggrecan.
COL2: collagen type-II. COL1: collagen type-I. n.d.: not detectable.
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tissue, whenever present, as well as osteocytes and blood
vessels showed reactivity for PHA-E, whereas subchondral
bone matrix was not stained (not shown).
PHA-L neither bound to chondrocytes nor to inter-
territorial matrix of mildly degenerated cartilage regions
(0/7; 0%). In comparison, positive chondrocytes and inter-
territorial matrix were detected in 22% (2/9) and 11 % (1/9)
of severely degenerated areas, respectively (Figure 2h).
Similar to PHA-E, PHA-L preferentially stained com-
plex chondrons. Cells of the pannus-like tissue, blood
vessels and parts of the subchondral bone matrix
presented PHA-L reactivity (not shown).
VAA, negative in areas of mild degeneration (0/7;
Figure 2i), reacted with chondrons and interterritorital
matrix of severely affected regions (3/9; Figure 2j;
Additional file 3: Table S3). The subchondral bone matrix
and blood vessels were stained too, but not the pannus-
like tissue (not shown).
LEA binding was selective for chondrons and inter-
territorial matrix in 22% (2/9) of severely degenerated
cartilage regions (Figure 2k; Additional file 3: Table S3). In
addition, the subchondral bone matrix was positive in the
two reactive specimens. Less affected areas (0%; 0/7),
pannus-like tissue, blood vessels and osteocytes were
negative (not shown).
MAA-I did not react with chondrons and matrix of
mildly degenerated cartilage areas (0/9; 0%). In 44% (4/9)
of severely degenerated regions, reactivity for MAA-I was
observed in the chondrons and, in 56% (5/9) of severely
degenerated areas, the interterritorial matrix was also
positive (Figure 2l; Additional file 3: Table S3). Pannus-like
tissue was positive whenever present, whereas blood ves-
sels or the subchondral bone presented no reactivity (not
shown).
SNA was rarely reactive with chondrons and matrix
in cartilage regions of mild degeneration (1/7; 14%;
Additional file 3: Table S3, Figure 2m). In comparison,
44% (4/9) of severely degenerated areas presented reactive
chondrons, while 22% (2/9) of these regions showed re-
activity for interterritorial matrix (Figure 2n). Pannus-like
tissue, blood vessels and subchondral bone were negative
(not shown).
DBA stained chondrons only in areas of severe degen-
eration (22%; 2/9; Figure 2o; Additional file 3: Table S3).
The interterritorial matrix presented staining in a com-
parable amount of areas of mild (29%; 2/7) and severe
Figure 1 Major glycan structures found in OA chondrocytes. Major N-glycan and O-glycan species, that is, oligomannosidic structures,
non-, mono- and disialylated N-glycans, β4GalNAc-containing N-glycans as well as mucin-type core 2 O-glycans, were identified and quantified
independently in chondrocytes from three patients by LC–ESI-MS. Results shown were obtained from chondrocytes of one patient (n = 1) and
are representative of three independent experiments with similar results. Glycans are referred to according to the ‘proglycan’ nomenclature
(http://www.proglycan.com). The oligosaccharides shown here were selected for quantification with LC-ESI-MS, because they are among the most
abundant glycan structures in human chondrocytes and are essentially absent in the glycome of the fetal calf serum-containing cell culture
medium, which can otherwise contaminate the chondrocyte glycome to some extent. As a measure of quantity the mean peak area values
obtained by LC–ESI-MS are given for each structure. For each peak area, the standard deviation resulting from two technical replicates was below
15%. LC–ESI-MS, liquid chromatography-electrospray ionization-mass spectrometry; OA, osteoarthritis.
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Figure 2 Lectin histochemical staining profiles in sections of OA cartilage. (a) Binding of PNA to complex chondrons of a severely
degenerated cartilage region could be completely blocked with lactose (inset) ascertaining carbohydrate-specific binding. (b) Omission of the
incubation step with biotinylated LEA (first-step reagent) from processing excluded probe-independent signal generation. (c, d) ConA staining:
staining pattern of MS ≤4 regions included chondrocytes in deep zones of cartilage (c). Intense staining of matrix and chondrons (inset) in MS
≥9 regions (d). (e) PSA staining: positivity of chondrons (inset) and matrix, predominantly in MS ≥9 cartilage. (f, g) PHA-E staining: whereas MS
≤4 regions were negative (f), MS ≥9 areas (g) presented positive chondrons (inset) and matrix. (h) PHA-L staining: binding sites were restricted to
chondrons (insert) and matrix of MS ≥9 cartilage. (i-j) VAA staining: whereas the chondrons of MS ≤4 areas were negative (i), reactivity was
observed both in chondrons (inset) and matrix of MS ≥9 cartilage (j). (k) LEA staining: reactivity for chondrons (inset) and matrix of MS ≥9
regions. (l) MAA-I staining: reactivity included chondrons (inset) and matrix of MS ≥9 cartilage. (m, n) SNA staining: weak staining of matrix and
no staining of chondrons in MS ≤4 cartilage (m), whereas both chondrons (inset) and matrix were positive in MS ≥9 regions (n). (o) DBA
staining: positivity in chondrons (inset) and matrix of MS ≥9 cartilage. (p, q) PNA staining: positive chondrocytes sparely distributed in the deeper
zones of MS ≤4 cartilage (p; arrows, inset). In MS ≥9 cartilage (q), intense matrix staining was observed, whereas chondrons were mostly
negative (inset). (r) JAC staining: absent in chondrons (inset), but present in superficial zones of MS ≥9 cartilage. Bars in inserts of d,e,g,l,n,p,q,r:
50μm. Bars in inserts of h,j,k,o: 100μm. MS, Mankin score; OA, osteoarthritis.
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degeneration (33%; 3/9). Pannus-like tissue reactivity
was observed in one out of two cases. Blood vessels and
the subchondral bone were unstained throughout all
samples (not shown).
PNA reacted with chondrons of all mildly degenerated
cartilage regions (100%; 7/7; Figure 2p). Interestingly,
only 67% (6/9) of the severely degenerated regions
showed PNA-positive chondrons (see Additional file 3:
Table S3). In contrast, interterritorial matrix was positive
in only 43% (3/7) of less affected areas, whereas a
marked increase and intensive staining was observed
in more affected regions (100%; 9/9; Figure 2q). The
pannus-like tissue gave signals whenever present. In five
cases, PNA staining was observed in osteocytes, whereas
in the subchondral bone matrix no staining was found
(not shown).
JAC bound the interterritorial matrix in the proximity
of surface fissures in three out of nine cases of severely
degenerated regions (33%; Additional file 3: Table S3).
Interestingly, chondrons were negative, resulting in
characteristic, unstained regions around chondrocytes
(Figure 2r). In those three specimens, the subchondral
bone matrix was also positive. In contrast, mildly degene-
rated cartilage areas exhibited no staining of cells or
matrix. Furthermore, pannus-like tissue, blood vessels or
osteocytes were negative.
These data define the glycophenotype of OA cartilage
with respect to distinct carbohydrate determinants. Mov-
ing from plant to human lectins as probes to strengthen
the aspect of potential physiological implications, we next
applied two human lectins, that is, Gal-1 and Gal-3, to the
cartilage sections. In addition to their reactivity to glycans
Figure 3 Binding sites of human galectins in OA cartilage. (a): OA cartilage from five donors was histologically processed and stained with
labeled Gal-1 and Gal-3, respectively. Positivity of chondrons and interterritorial matrix was assessed microscopically for MS ≥9 and MS ≤4 regions
separately. The percentages given at the bottom of the table refer to the fractions of specimens presenting stained chondrons or interterritorial
matrix among all analyzed OA cartilage specimens (n = 5). − no staining; + moderate staining; ++ intense staining; MS: Mankin score (b, c): Gal-1
staining: reactivity included the matrix of MS ≤4 (b) and MS ≥9 (c) regions of OA cartilage. Insets show negativity of chondrons. (d, e): Gal-3
staining: In MS ≤4 regions (d), no staining of chondrocytes and matrix, whereas in MS ≥9 regions (e) reactivity for both chondrons and matrix
was observed. Bars in inserts of (b-e): 50μm. Gal-1, galectin-1, Gal-3, galectin-3, OA, osteoarthritis.
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(please see Table 1 for details), these endogenous effectors
can also react with distinct proteins intracellularly.
Glycophenotyping with human galectins
The interterritorial matrix of all mildly and severely
degenerated cartilage areas was positive for Gal-1 (5/5,
100%; Figure 3a). In comparison to less affected areas
(Figure 3b), however, most of the more degenerated
areas exhibited an intense staining reactivity (Figure 3c).
No staining was observed in chondrons, regardless of
the degeneration status of cartilage. Moreover, osteo-
cytes and the subchondral bone matrix were negative,
whereas blood vessels were reactive (not shown).
Mildly degenerated cartilage, especially the matrix, was
rarely positive for Gal-3 (Figure 3a, d). In contrast, this
lectin stained – partly intensely – chondrons (5/5) and
interterritorial matrix (4/5) of most severely degenerated
cartilage specimens (Figure 3a, e). Pannus-like tissue,
whenever present, was also positive.
Regarding the detection of LacdiNAc-presenting N-
glycans and core 2 O-glycans it should be noted that
LacdiNAc is known as ligand for Gal-3, for which core
2 branching is not a favorable factor [44,45]. Having here-
with proven the presence of galectin-binding sites and
illustrated their spatial distribution, we became interested
to reveal whether tissue galectins were expressed in OA
cartilage. Thus, we employed labeled ASF, known to serve
as a pan-galectin sensor [30].
Glycohistochemical analysis
Using sections of human quadriceps muscle as internal
control for the reactivity of labeled ASF [46], application
of this probe was optimized. Its enzymatic deglyc-
osylation completely abolished binding in controls,
underscoring the crucial role of glycan binding (not
shown). The majority of arthritic cartilage areas (89%;
8/9) presented ASF staining of chondrons and inter-
territorial matrix (Figure 4a). In three cases, a particu-
larly intense signal was observed, whereas one specimen
did not respond to ASF (see Additional file 3: Table S3). In
addition, reactivity was also observed in the pannus-like
tissue. In areas of mild degeneration, chondrons and
matrix were less frequently stained (43%; 3/7; Figure 4b).
Subchondral bone was negative; blood vessels were weakly
positive (not shown).
In quantitative comparison, ASF-positive cells were
present in significantly higher rates in severely degenerated
areas than in mildly degenerated areas (Figure 4c). At the
Figure 4 Binding sites for ASF in human OA cartilage and chondrocytes. (a, b) Reactivity for ASF in OA cartilage. (a) Intense reactivity of
ASF with chondrocytes and matrix of MS ≥9 cartilage. The inset shows stained complex chondrons. (b) In MS ≤4 regions, positive chondrocytes
were scattered across the superficial zone of cartilage (inset and arrows). Bars in insets of (a) and (b): 50 μm. (c) Shown is a quantitative
comparison between MS ≤4 and MS ≥9 regions of OA cartilage. Each bar represents the mean percentage of stained (reactive for ASF)
chondrons in the respective areas (n = 7; see Additional file 3: Table S3). The asterisk indicates a significant difference of cell reactivity between
cartilage areas of mild and severe degeneration (P = 0.0015; n = 7; paired t-test). (d) Subcellular distribution of ASF reactivity in cultured OA
chondrocytes. Cells were incubated with biotinylated ASF and stained with streptavidin-phycoerythrin. ASF reactivity (red) was observed using
laser scanning microscopy. Nuclei were counterstained with DAPI (blue). ASF, asialofetuin; DAPI, 4′,6-diamidino-2-phenylindole; MS, Mankin score;
OA, osteoarthritis; PE, phycoerythrin.
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subcellular level, ASF binding was seen in a fine-
granular manner throughout the cytoplasm whereas the
nucleus and the cell membrane were consistently nega-
tive (Figure 4d).
Discussion
This study was designed to characterize the glyco-
phenotype of OA cartilage using human chondrocytes
in vitro and lectin histochemical analysis of clinical speci-
mens. Initially, we monitored glycosyltransferase mRNA
levels as well as N- and O-glycans (excluding glycans
present in the used serum in the culture medium) by RT-
qPCR and by LC-ESI-MS, respectively. The presented
quantitative data, encouraging detailed glycogene moni-
toring (for example, β1,3/4-galactosyltransferases or glyco-
hydrolases such as sialidases), gave reason for selecting a
panel of plant lectins for the histochemical investigations.
In this context, we focused on lectins targeting substitu-
tions of the N-glycan core, which are potent switches for
conformational behavior and reactivity for tissue lectins
[12,47], presence of LacNAc repeats and the status of
sialylation. Owing to previous indications for plant lectins
(that is, ConA and wheat germ agglutinin) to act as probes
for degenerative joint diseases [48], we also included
ConA. The semiquantitative assessment of stained OA
cartilage defined the presence and localization of
plant-lectin-reactive glycan epitopes. An enzymatic pre-
treatment to remove glycosaminoglycans was deliberately
not performed to avoid non-physiological alteration of ac-
cessibility to probes, especially in view of the binding of
the human galectins. Most importantly, it delineated dif-
ferences with respect to the degeneration grade of cartil-
age within the patients (as determined using the MS) in
certain cases. In particular, altered staining frequency and
intensity were observed for lectins specific for (1) α2,3-
sialylation of LacNAc-terminated N-glycans, (2) galacto-
sides (reactive with VAA) and (3) bisected N-glycans (the
bisecting GlcNAc residue acts on the local density of
branch-end epitopes and may affect recognition processes
directly or indirectly [47,49]). Since distinct sugar epitopes
are the docking sites for tissue lectins to turn glyco-
conjugates into the ligand part of functional counter-
receptors, we next applied two human adhesion/
growth-regulatory lectins, that is, Gal-1 and Gal-3, as
histochemical tools.
The respective results illustrate the feasibility of this
application and show differences between the binding
patterns of the two tested galectins. Whereas the
interterritorial matrix of cartilage and blood vessels were
the main sites of Gal-1 reactivity, chondrons and
pannus-like tissue bound Gal-3. Of note, isolated OA
chondrocytes, as previously observed for samples of rab-
bits with articular cartilage deterioration [50], presented
N-glycans with the LacdiNAc terminus, a binding part-
ner for Gal-3 but not for Gal-1.
Based on these findings, it can be postulated that
galectins should be present in OA cartilage as on-site
effectors that can translate the sugar code of cells and
matrix into biological functions. The presence of binding
sites for the glycoprotein ASF, whose glycans bind rather
equally well to the human galectins [51], underscores
this assumption. In fact, our data revealed an increase of
ASF reactivity of OA cartilage as a function of the MS,
suggesting elevated levels of galectins in areas of cartilage
degeneration. Of relevance for joint diseases, Gal-3 was
shown to localize in the synovium obtained from rheuma-
toid arthritis patients at the sites of cartilage and bone
destruction, whereas Gal-1 was detected mostly in the
sublining layer [52]. In addition, other galectins including
galectins-8 and -9 appear of interest. Galectin-8 is widely
expressed in human tissues and tumors [53,54] and, to
emphasize potential orthopedic relevance, is produced
and secreted by human synovial fluid cells in patients with
rheumatoid arthritis [55]. Detection of autoantibodies
against this and other galectins in sera of respective pa-
tients has been reported [56]. Interestingly, a clinical asso-
ciation of a single nucleotide polymorphism in the coding
region of the galectin-8 gene (that is, the F19Y substitu-
tion) was recently revealed with rheumatoid arthritis [57].
Conclusions
In summary, the present study adds to the charac-
terization of the glycophenotype of chondrocytes and
matrix in OA, with special emphasis on clinical speci-
mens. In particular, it reports first insights into the re-
activity of OA cartilage with tissue effectors and thereby
gives further work on endogenous lectins a clear direc-
tion: systematic monitoring to define the localization of
galectins by immunohistochemical fingerprinting in OA,
along with monitoring binding-site availability and target
glycoproteins, and the in vitro testing of galectins in
relevant cell models.
Additional files
Additional file 1: Table S1. Characteristics of clinical specimens. OA
cartilage was obtained from OA patients (age range 54 to 80 years)
between September 2010 and April 2012 according to the protocol
given in the Methods section.
Additional file 2: Table S2. MIQE checklist of RT-qPCR assays.
Additional file 3: Table S3. Localization of lectin-reactive glycans in OA
cartilage.
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